1
|
Padole P, Arora A, Sharma P, Chand P, Verma N, Kumar A. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients. J Clin Exp Hepatol 2022; 12:435-439. [PMID: 35535066 PMCID: PMC9077151 DOI: 10.1016/j.jceh.2021.06.015] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2021] [Accepted: 06/12/2021] [Indexed: 12/12/2022] Open
Abstract
Background Saroglitazar is a novel, dual peroxisome proliferator-activated receptors-α/γ agonist and is being investigated for the treatment of nonalcoholic fatty liver disease (NAFLD). Patients and methods Consecutive overweight (body mass index [BMI] >23 kg/m2) patients of NAFLD, diagnosed based on controlled attenuation parameter (CAP) >248 dB/m, and attending the outpatient department of a tertiary care centre in New Delhi, were enrolled. Patients with cirrhosis (liver stiffness measurement [LSM] >13.5 kPa) and those with concomitant liver disease due to other aetiologies (alcohol, viral, etc.) were excluded. All patients received saroglitazar 4 mg/day; in addition, they were advised to reduce weight and were counselled regarding diet and exercise. At 3-month follow-up, patients were categorized into those who were able to reduce ≥5% body weight and those who could n'ot, and both these groups were compared. Results A total of 91 patients (median age 45 years [range 18-66 years]; 81% men) were included in the study. The median BMI was 29.3 kg/m2 (range 23.6-42.2 kg/m2). The baseline median (range) aspartate transaminase, alanine transaminase, gamma glutamyl transferase, LSM and CAP values were 40 IU/dL (range 22-144 IU/dL), 48 IU/dL (range 13-164 IU/dL), 42 IU/dL (range 4-171 IU/dL), 6.7 kPa (range 3.6-13.1 kPa), and 308 dB/m (range 249-400 dB/m). All patients tolerated saroglitazar well. At 3-month, 57 patients (63%) were able to reduce ≥5% weight, whereas in the remaining 34 patients (37%), the weight reduction was <5% from baseline. Transaminases values improved in both the groups; however, LSM and CAP values improved only in patients who reduced weight. Conclusion In overweight patients with NAFLD, a 3-month therapy with saroglitazar is able to improve transaminases but not LSM and CAP values unless accompanied by weight reduction of at least 5%. Larger randomized controlled trials are needed to document the independent effect of saroglitazar in these patients.
Collapse
Key Words
- ALP, alkaline phosphatase
- ALT, alanine transaminase
- AST, aspartate transaminase
- BMI, body mass index
- CAP, controlled attenuation parameter
- DCGI, Drug Controller General of India
- FDA, Food and Drug Administration
- GGT, gamma glutamyl transferase
- HCV, hepatitis C virus
- IQR, interquartile range
- IU, international units
- LSM, liver stiffness measurement
- MAFLD, metabolic (dysfunction) associated fatty liver disease
- NAFLD
- NAFLD, nonalcoholic fatty liver disease
- NASH, nonalcoholic steatohepatitis
- PPAR, peroxisome proliferator-activated receptor
- controlled attenuation parameter
- dB, decibels
- kPa, kilopascal
- obesity
- pPAR agonist
- saroglitazar
Collapse
Affiliation(s)
- Prateek Padole
- Institute of Liver, Gastroenterology, and Pancreatico-Biliary Sciences, Sir Ganga Ram Hospital, New Delhi, India
| | - Anil Arora
- Institute of Liver, Gastroenterology, and Pancreatico-Biliary Sciences, Sir Ganga Ram Hospital, New Delhi, India
| | - Praveen Sharma
- Institute of Liver, Gastroenterology, and Pancreatico-Biliary Sciences, Sir Ganga Ram Hospital, New Delhi, India
| | - Prakash Chand
- Institute of Liver, Gastroenterology, and Pancreatico-Biliary Sciences, Sir Ganga Ram Hospital, New Delhi, India
| | - Nishant Verma
- Institute of Liver, Gastroenterology, and Pancreatico-Biliary Sciences, Sir Ganga Ram Hospital, New Delhi, India
| | - Ashish Kumar
- Institute of Liver, Gastroenterology, and Pancreatico-Biliary Sciences, Sir Ganga Ram Hospital, New Delhi, India
| |
Collapse
|
2
|
Rajesh N, Drishya L, Ambati MMR, Narayanan AL, Alex M, R KK, Abraham JJ, Vijayakumar T. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study. J Clin Exp Hepatol 2022; 12:61-67. [PMID: 35068786 PMCID: PMC8766544 DOI: 10.1016/j.jceh.2021.03.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Accepted: 03/28/2021] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND Saroglitazar-a unique dual peroxisome proliferator-activated receptor agonist was approved marketing authorization in India in 2013 for diabetic dyslipidemia. Postmarketing studies have additionally shown improvement in liver parameters in diabetic dyslipidemia patients with nonalcoholic fatty liver disease (NAFLD) who received saroglitazar. AIM The aim of this study was to evaluate the effect of saroglitazar on liver function test, liver fibrosis score by FibroScan, lipid profiles, HbA1c in NAFLD patients with diabetic dyslipidemia in southern India. METHODOLOGY A prospective, interventional, pilot study was performed to study the safety and efficacy of saroglitazar in NAFLD patients having type 2 diabetes mellitus. About 97 patients were screened, of which 85 patients were involved in the study based on the inclusion criteria. The clinical parameters and liver stiffness were measured at the baseline and also after 12 weeks of treatment with administration of saroglitazar 4 mg once daily. The change in the parameters at the baseline and after the end of the treatment was measured and was subjected to statistical analysis using SPSS software. RESULTS The recruited patients received saroglitazar and were followed up for a period of 12 weeks. The clinical parameters such as fasting blood sugar, postprandial blood sugar, HbA1c, total cholesterol, triglycerides, SGPT, and liver stiffness showed significant difference after 12 weeks of treatment when compared with the baseline values. No adverse drug reaction was reported in patients receiving saroglitazar during the study. CONCLUSION Saroglitazar was found to show significant improvement in liver parameters in NAFLD patients with a significant reduction in liver fibrosis and triglycerides level.
Collapse
Key Words
- AACE, American Associaton of Clinical Endocrinologists
- ADR, Adverse Drug Reaction
- ALT, Alanine Transaminase
- BMI, Body Mass Index
- CDSCO, Central Drugs Standard Control Organisation
- CT Scan, Computed Tomography Scan
- DBP, Diastolic Blood Pressure
- DCGI, Drug Controller General of India
- FBS, Fasting Blood Sugar
- GLP1Ra, Glucagon Like Peptide 1 Receptor agonist
- HCV, Hepatitis - C Virus
- HDL, High Density Lipoprotein
- HbA1C, Glycated Hemoglobin
- IHEC, Institutional Human Ethics Committee
- LDL-C, Low Density Lipoprotein Cholesterol
- LSM, Liver Stiffness Measurement
- MRI, Magnetic Resonance Imaging
- NAFLD, Nonalcoholic Fatty Liver Disease
- NASH, Non-Alcoholic Steatohepatitis
- NPV, Negative Predictive Value
- Na2EDTA, Sodium Ethylenedinitrilotetraacetic acid
- PPAR, Peroxisome Proliferator Activated Receptor
- PPBS, Post Prandial Blood Sugar
- SBP, Systolic Blood Pressure
- SDB, Serum Direct Bilirubin
- SGLT2i, Sodium Glucose Co-Transporter-2 Inhibitor
- SGOT, Serum Glutamate Oxaloacetic Transaminase
- SGPT, Serum Glutamate Pyruvic Transaminase
- SPSS, Statistical Package for the Social Sciences
- STB, Serum Total Bilirubin
- T2DM, Type 2 Diabetes Mellitus
- TC, Total Cholesterol
- TG, Triglycerides
- TZD, Thiazolidinediones
- USG, Ultra Sonography
- VLDL, Very Low Density Lipoprotein
- diabetic dyslipidemia
- fibrosis level
- non-alcoholic fatty liver disease
- saroglitazar
- ultrasound
Collapse
Affiliation(s)
- N.A. Rajesh
- Department of Medical Gastroenterology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India
| | - L. Drishya
- Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India
| | - Murali Mohan Raju Ambati
- Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India
| | - Athi L. Narayanan
- Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India
| | - Maria Alex
- Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India
| | - Kiran Kumar R
- Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India
| | - Justin J. Abraham
- Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India
| | - T.M. Vijayakumar
- Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India
- Address for correspondence: Dr. T.M. Vijayakumar, M.Pharm, Ph.D., Associate Professor & Head, Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, 603 203, India. Tel.: +91 44 2745 3160, +91 44 2745 5718; Fax: +91 44 2745 5734.
| |
Collapse
|
3
|
Abstract
A growing number of innovative mAb therapeutics are on the global market, and biosimilar versions have now also been approved, including in India. Although efficacy and safety is demonstrated prior to approval, targeted pharmacovigilance is essential for the identification and assessment of risk for any mAb products. We analyzed the ADR data related to mAbs reported to the NCC-PvPI through the spontaneous reporting system Vigiflow during April 2011 to February 2014 to identify mAbs with the highest number of ADR including fatal/serious ADR. Only 0.72% reports were related to mAbs. Although 15 mAbs are approved in the country, only 6 mAbs were reported through Vigiflow. Rituximab was highly reported, and no fatal/serious ADR related to any mAbs were reported during the study period. Our study shows that PvPI is effective and robust system in the detection and assessment of risks associated with the use of mAbs.
Collapse
Key Words
- ADR, adverse drug reactions
- ADR/E, adverse drug reactions/event
- AMCs, ADR monitoring centers
- CDSCO, Central Drugs Standard Control Organization
- CLL, chronic lymphocytic leukemia
- DCGI, Drug Controller General of India
- EMA, European Medicines Agency
- EU, European Union
- GEAC, Genetic Engineering Appraisal Committee
- HBV, hepatitis B virus
- ICSRs, Individual Case Safety Reports
- IPC, Indian Pharmacopoeia Commission
- MHRA, Medicines and Healthcare Products Regulatory Agency
- MedDRA, Medical Dictionary for Regulatory Activities
- MoEF, Ministry of Environment and Forests
- MoHFW, Ministry of Health and Family Welfare
- NCC-PvPI
- NCC-PvPI, National Coordination Centre-Pharmacovigilance Program of India
- NHL, non Hodgkin lymphoma
- NRA, National Regulatory Authority
- PML, progressive multifocal leukoencephalopathy
- PSUR, Periodic Safety Updates Report
- RCGM, Review Committee on Genetic Manipulation
- SOC, System Organ Class
- US, Unites States of America
- USFDA, United States Food and Drug Administration
- Vigiflow
- WHO, World Health Organization
- mAb, monoclonal antibody
- mAbs, monoclonal antibodies
- monoclonal antibody
- rDNA, recombinant DNA
- spontaneous reporting
- targeted pharmacovigilance
Collapse
Affiliation(s)
- M Kalaivani
- a Scientific Assistant; Biologics Section; Indian Pharmacopoeia Commission ; Ministry of Health and Family Welfare (Govt. of India) ; Ghaziabad , India
| | | | | |
Collapse
|